US009636461B2

(12) **United States Patent**
Bengtsson et al.

(10) **Patent No.: US 9,636,461 B2**
(45) **Date of Patent: May 2, 2017**

(54) **SYSTEM FOR OPTIMIZING A DRUG DOSAGE REGIMEN OVER TIME**

(75) Inventors: **Henrik Bengtsson**, Taastrup (DK); **Toke Folke Christensen**, Soeborg (DK)

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 81 days.

(21) Appl. No.: **14/115,799**

(22) PCT Filed: **May 2, 2012**

(86) PCT No.: **PCT/EP2012/058035**
§ 371 (c)(1),
(2), (4) Date: **Feb. 19, 2014**

(87) PCT Pub. No.: **WO2012/152628**
PCT Pub. Date: **Nov. 15, 2012**

(65) **Prior Publication Data**

US 2014/0200545 A1 Jul. 17, 2014

Related U.S. Application Data

(60) Provisional application No. 61/485,291, filed on May 12, 2011.

(30) **Foreign Application Priority Data**

May 6, 2011 (EP) 11165063

(51) **Int. Cl.**
A61M 5/24 (2006.01)
G06F 19/00 (2011.01)
(Continued)

(52) **U.S. Cl.**
CPC ***A61M 5/24*** (2013.01); ***A61B 5/14532*** (2013.01); ***A61M 5/3157*** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC A61M 5/1723; A61M 2005/1726; A61M 2230/201; A61M 5/14244;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,731,726 A 3/1988 Allen, III
6,192,891 B1 * 2/2001 Gravel et al. 604/187
(Continued)

FOREIGN PATENT DOCUMENTS

CN 101125086 A 2/2008
EP 1048310 A2 11/2000
(Continued)

OTHER PUBLICATIONS

Blonde, L. et al., Patient-Directed Tritation for Achieving Glycaemic Goals Using a Once-Daily Basal Analogue: An Assessment of Two Different Fasting Plasma Glucose Targets, Daibetes, Obesity and Metabolism, vol. 11, 2009, pp. 623-631.

Primary Examiner — Imani Hayman
Assistant Examiner — Hamza Darb
(74) *Attorney, Agent, or Firm* — Leon Y. Lum

(57) **ABSTRACT**

A system for optimizing a patient's basal insulin dosage regimen over time, adapted to determine from blood glucose values whether and by how much to vary a patient's present recommended amount of the insulin-containing drug in order to maintain the patient's future blood glucose level measurements within a predefined range, and wherein a given blood glucose value is disregarded if no patient-actuated operation being indicative of the administration of a dose of an insulin containing drug has been detected in a pre-defined amount of time prior to the determination of the given blood glucose value.

10 Claims, 7 Drawing Sheets